Skip to main content

Advertisement

SpringerLink
Log in

Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

In patients with systemic lupus erythematosus (SLE), low bone mineral density (BMD) is associated with increased age, prolonged disease, low body mass index (BMI), and overlap with rheumatoid arthritis (RA). Elevated fibroblast growth factor (FGF)-23 in cyclosporine A (CsA) users with SLE are associated with decreased active vitamin D and osteocalcin.

Introduction

The objective of this study was to investigate the steroid and CsA effect on bone metabolism and serum FGF-23 in SLE patients.

Methods

Seventy-two SLE patients and 10 age- and sex-matched healthy individuals underwent blood tests for bone metabolic biomarkers and FGF-23, and lumbar spine dual-energy X-ray absorptiometry for BMD.

Results

Comparisons between patients and controls were made in premenopausal women/men younger than 50 years and postmenopausal women/men older than 50 years separately. SLE patients had more frequent low Z-score (≤ − 2.0, 8.5 vs. 0 %), osteopenia (−2.5 < T-score < −1.0, 52 vs. 50 %), and osteoporosis (T-score ≤ −2.5, 12 vs. 0 %), than the healthy age-compatible counterparts. BMD was significantly lower in patients with advanced age, longer disease duration, lower BMI, and overlap with RA (all p < 0.05 by multiple linear regression analyses). Serum FGF-23 was significantly higher and 1,25-dihydroxyvitamin D (1,25(OH)2D3) lower in SLE patients treated with glucocorticoid and CsA than in those not taking both of them (p = 0.027 and 0.002, respectively). The cumulative dose of glucocorticoid was inversely correlated with serum intact parathyroid hormone (r = −0.299, p = 0.011), C-terminal telopeptide of type I collagen (r = −0.581, p < 0.001), and osteocalcin (r = −0.648, p < 0.001). FGF-23 and the cumulative dose of CsA were positively correlated (r = 0.38, p = 0.001) and both were negatively correlated with 1,25(OH)2D3 (r = −0.266, p = 0.016 and r = −0.55, p < 0.001) and osteocalcin (r = −0.234, p = 0.034 and r = −0.274, p = 0.02).

Conclusion

SLE patients treated with glucocorticoid and CsA exhibited markedly decreased bone turnover. Those taking CsA had higher serum FGF-23 associated with suppression of 1,25(OH)2D3 and bone formation. Such high-risk patients necessitate regular screening of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Movsowitz C, Epstein S, Ismail F, Fallon M, Thomas S (1989) Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption. J Bone Miner Res 4:393–398

    Article  CAS  PubMed  Google Scholar 

  2. Lane NE, Lukert B (1998) The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 27:465–483

    Article  CAS  PubMed  Google Scholar 

  3. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, Takayanagi H (2005) NFAT and Osterix cooperatively regulate bone formation. Nat Med 11:880–885

    Article  CAS  PubMed  Google Scholar 

  4. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39:1383–1389

    Article  Google Scholar 

  5. Bultink IE, Harvey NC, Lalmohamed A, Cooper C, Lems WF, van Staa TP, de Vries F (2014) Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 25:1275–1283

    Article  CAS  PubMed  Google Scholar 

  6. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561–568

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Baum M, Schiavi S, Dwarakanath V, Quigley R (2005) Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int 68:1148–1153

    Article  CAS  PubMed  Google Scholar 

  8. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T (2004) FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429–435

    Article  CAS  PubMed  Google Scholar 

  9. Krajisnik T, Björklund P, Marsell R, Ljunggren O, Akerström G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125–131

    Article  CAS  PubMed  Google Scholar 

  10. Celik E, Guzel S, Abali R, Guzelant AY, Celik Guzel E, Kuçukyalcin V (2013) The relationship between fibroblast growth factor 23 and osteoporosis in postmenopausal women. Minerva Med 104:497–504

    CAS  PubMed  Google Scholar 

  11. Mirza MA, Karlsson MK, Mellström D, Orwoll E, Ohlsson C, Ljunggren O, Larsson TE (2011) Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 26:857–864

    Article  PubMed  Google Scholar 

  12. Toloza SM, Cole DE, Gladman DD, Ibañez D, Urowitz MB (2010) Vitamin D insufficiency in a large female SLE cohort. Lupus 19:13–19

    Article  CAS  PubMed  Google Scholar 

  13. Souto M, Coelho A, Guo C, Mendonca L, Argolo S, Papi J, Farias M (2011) Vitamin D insufficiency in Brazilian patients with SLE: prevalence, associated factors, and relationship with activity. Lupus 20:1019–1026

    Article  CAS  PubMed  Google Scholar 

  14. Chaiamnuay S, Chailurkit LO, Narongroeknawin P, Asavatanabodee P, Laohajaroensombat S, Chaiamnuay P (2013) Current daily glucocorticoid use and serum creatinine levels are associated with lower 25(OH) vitamin D levels in Thai patients with systemic lupus erythematosus. J Clin Rheumatol 19:121–125

    Article  PubMed  Google Scholar 

  15. Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans BA, Lems WF, Voskuyl AE, Bultink IE (2013) Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 24:1827–1833

    Article  CAS  PubMed  Google Scholar 

  16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    Article  CAS  PubMed  Google Scholar 

  17. Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640

    Article  CAS  PubMed  Google Scholar 

  19. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S (2013) Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom 16:455–466

    Article  PubMed  Google Scholar 

  20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612

    Article  PubMed Central  PubMed  Google Scholar 

  21. Young A, Hodsman AB, Boudville N, Geddes C, Gill J, Goltzman D, Jassal SV, Klarenbach S, Knoll G, Muirhead N et al (2012) Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation. Am J Kidney Dis 59:761–769

    Article  CAS  PubMed  Google Scholar 

  22. Lee JJ, Aghdassi E, Cheung AM, Morrison S, Cymet A, Peeva V, Neville C, Hewitt S, DaCosta D, Pineau C et al (2012) Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. J Rheumatol 39:1378–1384

    Article  PubMed  Google Scholar 

  23. Pineau CA, Urowitz MB, Fortin PJ, Ibanez D, Gladman DD (2004) Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13:436–441

    Article  CAS  PubMed  Google Scholar 

  24. Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Escárcega RO, Jiménez-Hernández M, Etchegaray-Morales I, Soto-Vega E, Muñoz-Guarneros M, López-Colombo A, Delezé-Hinojosa M et al (2009) Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol 28:65–70

    Article  PubMed  Google Scholar 

  25. Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah S, Chow SK, Goh EM (2009) Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids. Lupus 18:178–181

    Article  CAS  PubMed  Google Scholar 

  26. Furukawa M, Kiyohara C, Tsukamoto H, Mitoma H, Kimoto Y, Uchino A, Nakagawa M, Oryoji K, Shimoda T, Akashi K et al (2011) Prevalence of and risk factors for low bone mineral density in Japanese female patients with systemic lupus erythematosus. Rheumatol Int 31:365–376

    Article  PubMed  Google Scholar 

  27. Souto MI, Coelho A, Guo C, Mendonca LM, Pinheiro MF, Papi JA, Farias ML (2012) The prevalence of low bone mineral density in Brazilian patients with systemic lupus erythematosus and its relationship with the disease damage index and other associated factors. J Clin Densitom 15:320–327

    Article  PubMed  Google Scholar 

  28. Li EK, Tam LS, Young RP, Ko GT, Li M, Lau EM (1998) Loss of bone mineral density in Chinese pre-menopausal women with systemic lupus erythematosus treated with corticosteroids. Br J Rheumatol 37:405–410

    Article  CAS  PubMed  Google Scholar 

  29. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N (2001) Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28:102–108

    CAS  PubMed  Google Scholar 

  30. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED (2007) Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 56:1966–1973

    Article  PubMed  Google Scholar 

  31. Sandhu SK, Hampson G (2011) The pathogenesis, diagnosis, investigation and management of osteoporosis. J Clin Pathol 64:1042–1050

    Article  CAS  PubMed  Google Scholar 

  32. Mok CC (2013) Vitamin D and systemic lupus erythematosus: an update. Expert Rev Clin Immunol 9:453–463

    Article  CAS  PubMed  Google Scholar 

  33. Baker-LePain JC, Nakamura MC, Shepherd J, von Scheven E (2011) Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford) 50:611–619

    Article  Google Scholar 

  34. Banno S, Matsumoto Y, Naniwa T, Hayami Y, Sugiura Y, Yoshinouchi T, Ueda R (2002) Reduced bone mineral density in Japanese premenopausal women with systemic lupus erythematosus treated with glucocorticoids. Mod Rheumatol 12:323–328

    Article  CAS  PubMed  Google Scholar 

  35. Yeo H, McDonald JM, Zayzafoon M (2006) NFATc1: a novel anabolic therapeutic target for osteoporosis. Ann N Y Acad Sci 1068:564–567

    Article  CAS  PubMed  Google Scholar 

  36. O’Regan S, Chesney RW, Hamstra A, Eisman JA, O’Gorman AM, Deluca HF (1979) Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand 68:109–111

    Article  PubMed  Google Scholar 

  37. Lee CT, Ng HY, Lien YH, Lai LW, Wu MS, Lin CR, Chen HC (2011) Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol 34:87–94

    Article  CAS  PubMed  Google Scholar 

  38. Kovalik M, Mellanby RJ, Evans H, Berry J, van den Broek AH, Thoday KL (2012) Ciclosporin therapy is associated with minimal changes in calcium metabolism in dogs with atopic dermatitis. Vet Dermatol 23:481–e491

    Article  PubMed  Google Scholar 

  39. Gesek FA, Friedman PA (1992) On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted tubule cells. J Clin Invest 90:749–758

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Wolf M, Koch TA, Bregman DB (2013) Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28:1793–1803

    Article  CAS  PubMed  Google Scholar 

  41. Lundberg S, Qureshi AR, Olivecrona S, Gunnarsson I, Jacobson SH, Larsson TE (2012) FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol 7:727–734

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, Shalhoub V, Mohammadi M, Pohl EE, Lanske B et al (2014) FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 33:229–246

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, Mariampillai K, Rosenzwajg M, Carpentier W, Musset L et al (2012) Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. Arthritis Res Ther 14:R221

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  44. Abou-Raya A, Abou-Raya S, Helmii M (2013) The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol 40:265–272

    Article  CAS  PubMed  Google Scholar 

  45. Austin HA 3rd, Illei GG, Braun MJ, Balow JE (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 20:901–911

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by intramural grants from the Taipei Veterans General Hospital (V101A-025, V102A-028, and V103A-002) and Ministry of Science & Technology (NSC 101-2314-B-075-030-MY3, NSC102-2314-B-075-067-MY3), Taiwan.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan

    C.-C. Lai, W.-S. Chen, Y.-P. Tsao, C.-T. Chou & C.-Y. Tsai

  2. Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital and National Defense Medical Center, Taipei, Taiwan

    D.-M. Chang

  3. Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan

    T.-H. Wu

  4. Division of Allergy, Immunology and Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taiwan, No. 201, Sec. 2, Shi-Pai Road, Taipei, 11217, Taiwan

    C.-Y. Tsai

Authors
  1. C.-C. Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W.-S. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D.-M. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y.-P. Tsao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T.-H. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C.-T. Chou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C.-Y. Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C.-Y. Tsai.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lai, CC., Chen, WS., Chang, DM. et al. Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only. Osteoporos Int 26, 601–610 (2015). https://doi.org/10.1007/s00198-014-2910-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-014-2910-3

Keywords

Search

Navigation